BNP Paribas Asset Management
STOK icon

BNP Paribas Asset Management’s Stoke Therapeutics STOK Stock Holding History

BNP Paribas Asset Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.1K Buy
648
+172
+36% +$5.64K ﹤0.01% 2019
2025
Q4 		$15K Buy
476
+159
+50% +$4.78K ﹤0.01% 2044
2025
Q3 		$7K Buy
+317
New +$5.43K ﹤0.01% 1747

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BNP Paribas Asset Management's STOK Position: Q1 2026 in Review

BNP Paribas Asset Management increased its Stoke Therapeutics (STOK) stake by 36% in Q1 2026, buying an estimated $5.64K and bringing the position to 648 shares worth $21.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2019.

BNP Paribas Asset Management first reported a position in STOK in Q3 2025 and has held it in 3 quarters since. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • BNP Paribas Asset Management held 648 shares of Stoke Therapeutics worth $21.1K as of Q1 2026.
  • BNP Paribas Asset Management bought 172 Stoke Therapeutics shares in Q1 2026, an estimated $5.64K.
  • Stoke Therapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q1 2026, its #2019 holding.
  • BNP Paribas Asset Management first reported a position in Stoke Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.